Legislators
Bills
Statements
Lobbying
Travel
- Bills
- H.R.5850
H.R.5850: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes
About This Bill
- Introduced Sept. 29, 2023
- Latest Major Action Oct. 6, 2023
Bill Sponsor
Bill Cosponsor
Bill Version
- Introduced in House - Sept. 29, 2023
Bill Actions
Date | Description |
---|---|
Oct. 6, 2023 |
Referred to the Subcommittee on Health.
|
Sept. 29, 2023 |
Referred to the House Committee on Energy and Commerce.
|
Sept. 29, 2023 |
Introduced in the House by Tracey Mann (R-Kan.) |